OPTN News and Press, OptiNose Inc. From 11/21/22

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and war...

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purch...

OptiNose, Inc. (OPTN) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Peter Miller - CEO Ramy Mahmoud - President and COO Conference Call Participants Glenn Santangelo...

OptiNose press release ( NASDAQ: OPTN ): Q3 GAAP EPS of -$0.18 in-line. Revenue of $20.1M (-7.9% Y/Y) misses by $3.3M . XHANCE Net Revenue and Average Net Revenue per Prescription: The company expects XHANCE net revenues for the full year of 2022 to be between...

Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Co...

YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College...

YARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2022 and corporate updates,...

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program Acute exacerbations of chronic sinusitis can lead to doctor visits, antibiotic us...

YARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen1 phase 3 clinical trial will be presented at the American Rhinol...

OptiNose, Inc. (OPTN) Q2 2022 Earnings Conference Call August 11, 2022 08:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Ramy Mahmoud - President and COO Vic Clavelli - Chief Commercial Officer Conference Call Participants Br...